Weight loss drugs have become an increasingly popular, but controversial, way of quickly shedding extra pounds over the past ...

GLP-1 drugs like Wegovy and Ozempic are designed to treat type 2 diabetes, but are widely known for their effect on weight ...

Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...

Federal regulators have accepted Novo Nordisk’s application to produce a pill version of its injectable weight-loss ...

Less than 3% of all people in the U.S. who are eligible for injectable weight loss drugs get a prescription for it, a new ...

In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical ...

With the active ingredients in drugs like Ozempic and Zepbound no longer in shortage, access to medicine for millions who had ...

In addition to requests for double-digit premium increases, Blue Cross Blue Shield of Vermont is also cutting back on coverage of popular weight-loss drugs on some plans.

People who take Wegovy appear to be at greater risk for hair loss, according to an early study that hasn't yet been ...

Zepbound — the brand name for tirzepatide — is the most effective GLP-1 medication for weight loss, according to one study.

Tirzepatide slashed weight by 20%, leading researchers to call this a new “golden age” for weight-loss therapies.